{"url_path":"/sec/oncy/8-k/2026-04-27/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000026-index.html","accession_number":"0001129928-26-000026","cik":"0001129928","ticker":"ONCY","issuer_name":"ONCOLYTICS BIOTECH INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1129928/0001129928-26-000026-index.html","primary_entity_key":"0001129928","primary_entity_name":"ONCOLYTICS BIOTECH INC"},"word_count":63,"has_tables":true,"body_markdown":"Item 8.01. Other Events.\n\nOn April 27, 2026, Oncolytics Biotech, Inc. (the “Company”) issued a press release announcing alignment with the U.S. Food and Drug Administration on plans for a controlled randomized pivotal study in squamous cell carcinoma of the anal canal. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference."}